儿童脱髓鞘与脑炎综合征与MOG抗体相关性的多中心观察研究
这项西班牙40中心前瞻性观察研究纳入239例脱髓鞘综合征和296例非ADEM脑炎患儿,发现116例MOG抗体阳性,其中脱髓鞘队列占39%、脑炎队列占7%。中位随访42个月,28%复发,85%预后良好(mRS<2);
要点
- 儿童MOG抗体相关疾病谱包括ADEM、脑炎、视神经炎、脊髓炎和NMOSD等。
- 非ADEM脑炎患儿中MOG抗体阳性率34%,高于所有神经元抗体合计的33%。
- ADEM样复发进展为脑白质营养不良样特征和广泛皮质脑炎演变为萎缩提示预后不良。
核心结论
- 儿童MOG抗体相关综合征谱比既往报道更广,涵盖脱髓鞘综合征和脑炎,识别这些疾病具有重要临床和预后意义。
研究设计与样本
- 西班牙40个二级和三级中心的前瞻性观察研究,纳入239例脱髓鞘综合征患儿(队列A)和296例非ADEM脑炎患儿(队列B),所有MOG抗体阳性者纳入分析。
主要发现
- 116例中就诊综合征包括ADEM 46例(68%)、非ADEM脑炎22例(19%)、视神经炎20例(17%)、脊髓炎13例(11%)、NMOSD 6例(5%)和其他9例(8%)。
- 队列B中64例自身免疫性脑炎患者,MOG抗体阳性22例(34%),高于所有神经元抗体合计的21例(33%)。
- 中位随访42个月(IQR 22-67),116例中33例(28%)复发,其中首诊时100例中17例(17%)复发。
关键数值与推荐
- 诊断时100例(86%)使用激素、静脉免疫球蛋白或血浆置换,复发时33例中32例(97%)使用。
- 利妥昔单抗主要在复发时使用(11例,33%)。
- 预后不良表型包括ADEM样复发进展为脑白质营养不良样特征,以及广泛皮质脑炎演变为萎缩。
临床怎么用
- 对儿童脱髓鞘综合征和非ADEM脑炎均应检测MOG抗体以识别相关疾病谱。
- ADEM样复发进展为脑白质营养不良样特征或广泛皮质脑炎演变为萎缩提示预后不良,需密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Investigations of myelin oligodendrocyte glycoprotein (MOG) antibodies are usually focused on demyelinating syndromes, but the entire spectrum of MOG antibody-associated syndromes in children is unknown. In this study, we aimed to determine the frequency and distribution of paediatric demyelinating and encephalitic syndromes with MOG antibodies, their response to treatment, and the phenotypes associated with poor prognosis. METHODS: In this prospective observational study, children with demyelinating syndromes and with encephalitis other than acute disseminated encephalomyelitis (ADEM) recruited from 40 secondary and tertiary centres in Spain were investigated for MOG antibodies. All MOG antibody-positive cases were included in our study, which assessed syndromes, treatment and response to treatment (ie, number of relapses), outcomes (measured with the modified Rankin scale [mRS]), and phenotypes associated with poor prognosis. We used Fisher's exact and Wilcoxon rank sum tests to analyse clinical features, and survival Cox regression to analyse time to antibody negativity. FINDINGS: Between June 1, 2013, and Dec 31, 2018, 239 children with demyelinating syndromes (cohort A) and 296 with encephalitis other than ADEM (cohort B) were recruited. 116 patients had MOG antibodies, including 94 (39%) from cohort A and 22 (7%) from cohort B; 57 (49%) were female, with a median age of 6·2 years (IQR 3·7-10·0). Presenting syndromes in these 116 patients included ADEM (46 [68%]), encephalitis other than ADEM (22 [19%]), optic neuritis (20 [17%]), myelitis (13 [11%]), neuromyelitis optica spectrum disorders (six [5%]), and other disorders (nine [8%]). Among the patients with autoimmune encephalitis in cohort B (n=64), MOG antibodies were more common than all neuronal antibodies combined (22 [34%] vs 21 [33%]). After a median follow-up of 42 months (IQR 22-67), 33 (28%) of the 116 patients had relapses, including 17 (17%) of 100 diagnosed at first episode. Steroids, intravenous immunoglobulin, or plasma exchange were used in 100 (86%) patients at diagnosis, and 32 (97%) of 33 at relapses. Rituximab was mainly used at relapses (11 [33%]). 99 (85%) of 116 patients had substantial recovery (mRS <2) and 17 (15%) moderate to severe deficits (mRS >2; one died). Phenotypes of poor prognosis included ADEM-like relapses progressing to leukodystrophy-like features, and extensive cortical encephalitis evolving to atrophy. Time to antibody negativity was longer in patients with relapses (HR 0·18, 95% CI 0·05-0·59). INTERPRETATION: The spectrum of paediatric MOG antibody-associated syndromes is wider than previously reported and includes demyelinating syndromes and encephalitis. Recognition of these disorders has important clinical and prognostic implications. FUNDING: Mutua Madrileña Foundation; ISCIII-Subdirección General de Evaluación y Fomento de la Investigación Sanitaria; Fondo Europeo de Desarrollo Regional; Pediatrics Spanish Society; Departament de Salut, Generalitat de Catalunya; Marato TV3 Foundation; Red Española de Esclerosis Múltiple; La Caixa Foundation; and Fundació CELLEX.
引用
- Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020. PMID: 32057303. doi:10.1016/S1474-4422(19)30488-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。